Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: Are they really the same?-Reference-Cited by-同舟云学术

Original and generic latanoprost for the treatment of glaucoma and ocular hypertension: Are they really the same?

Published:2015-01-12 Issue:2 Volume:42 Page:220-224
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:Clin Exp Pharmacol Physiol

Author:

Golan Shani¹,Rosenfeld Eldar¹,Shemesh Gabi¹,Kurtz Shimon¹

Affiliation:

1. Department of Ophthalmology; Tel Aviv Medical Centre, Tel Aviv, Israel affiliated with the Sackler Faculty of Medicine Tel Aviv University; Tel Aviv Israel

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1440-1681.12329/fullpdf

Reference21 articles.

1. The mechanism of action of prostaglandins on uveoscleral outflow;Schachtschabel;Curr. Opin. Ophthalmol.,2000

2. Isopropyl unoprostone increases the activity of matrix metalloproteinases in cultured monkey ciliary muscle cells;Kashiwaki;J. Glaucoma,2001

3. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow;Lindsey;Surv. Ophthalmol.,1997

4. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro;Lindsey;Invest. Ophthalmol. Vis. Sci.,1997

5. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey;Nilsson;Exp. Eye Res.,1989

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches;Pharmaceutics;2024-02-15

2. COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT);Expert Opinion on Drug Safety;2023-09-06

3. Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment;The Ocular Surface;2023-07

4. Persistence and adherence with Latanoprost: A Danish register‐based cohort study in older patients with glaucoma;Acta Ophthalmologica;2023-05-30

5. Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)—A Delphi Consensus Statement;American Journal of Ophthalmology;2022-09